Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 24.2% in August

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 695,800 shares, a decrease of 24.2% from the August 15th total of 917,400 shares. Based on an average daily volume of 3,490,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 4.6% of the shares of the stock are sold short.

In related news, SVP Eyal C. Attar sold 15,968 shares of the company’s stock in a transaction on Thursday, September 16th. The shares were sold at an average price of $4.68, for a total transaction of $74,730.24. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 18.60% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in APRE. SG Americas Securities LLC boosted its holdings in shares of Aprea Therapeutics by 2,725.9% in the 1st quarter. SG Americas Securities LLC now owns 655,888 shares of the company’s stock valued at $3,345,000 after buying an additional 632,678 shares in the last quarter. Morgan Stanley boosted its stake in Aprea Therapeutics by 111.0% in the 1st quarter. Morgan Stanley now owns 998,127 shares of the company’s stock worth $5,090,000 after purchasing an additional 525,106 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in Aprea Therapeutics in the 1st quarter worth approximately $1,551,000. Kennedy Capital Management Inc. boosted its stake in Aprea Therapeutics by 575.2% in the 2nd quarter. Kennedy Capital Management Inc. now owns 353,926 shares of the company’s stock worth $1,727,000 after purchasing an additional 301,511 shares in the last quarter. Finally, PDT Partners LLC acquired a new stake in Aprea Therapeutics in the 2nd quarter worth approximately $606,000. Institutional investors and hedge funds own 30.73% of the company’s stock.

NASDAQ:APRE opened at $4.67 on Wednesday. Aprea Therapeutics has a fifty-two week low of $3.17 and a fifty-two week high of $30.99. The stock has a market capitalization of $98.94 million and a P/E ratio of -2.08. The company’s 50-day simple moving average is $4.37 and its 200-day simple moving average is $4.69.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings results on Thursday, August 12th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). Equities analysts expect that Aprea Therapeutics will post -1.77 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on the stock. Berenberg Bank downgraded shares of Aprea Therapeutics from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research note on Monday, August 16th. JPMorgan Chase & Co. downgraded shares of Aprea Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Friday, August 20th. Royal Bank of Canada reduced their target price on shares of Aprea Therapeutics from $6.00 to $5.00 and set a “sector perform” rating on the stock in a research note on Friday, August 13th. Morgan Stanley downgraded shares of Aprea Therapeutics from an “equal weight” rating to an “underweight” rating and reduced their target price for the company from $5.00 to $3.00 in a research note on Thursday, August 12th. Finally, Zacks Investment Research downgraded shares of Aprea Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 4th. Two analysts have rated the stock with a sell rating and five have given a hold rating to the company. According to data from MarketBeat.com, Aprea Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $4.15.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers.

See Also: How to Trade Using Analysts Ratings

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.